HeartSciences Inc. Total Liabilities
HeartSciences Inc. total liabilities. Based on the latest financial reports, HeartSciences Inc. (HSCS) has total liabilities worth $5.77 Million USD as of July 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See HeartSciences Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of HeartSciences Inc. (2020–2026)
Total liabilities of HeartSciences Inc. from 2020 to 2026. This chart illustrates how HeartSciences Inc.'s total liabilities have evolved over time, based on quarterly financial data.
HeartSciences Inc. Competitors by Total Liabilities
The table below lists competitors of HeartSciences Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Megapolitan Developments Tbk
JK:EMDE
|
Indonesia | Rp1.23 Trillion |
|
Xintela AB
ST:XINT
|
Sweden | Skr36.95 Million |
|
P3 Health Partners Inc
NASDAQ:PIII
|
USA | $469.00 Million |
|
Investsmart Group Ltd
AU:INV
|
Australia | AU$6.41 Million |
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
USA | $853.63K |
|
Aksara Global Development Tbk PT
JK:GAMA
|
Indonesia | Rp328.54 Billion |
|
Norben Tea & Exports Limited
NSE:NORBTEAEXP
|
India | Rs133.61 Million |
|
CADOGAN ENERGY SOLUTIONS
F:CPD
|
Germany | €7.61 Million |
Liability Composition Analysis (2020–2026)
This chart breaks down HeartSciences Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of HeartSciences Inc..
Liquidity & Leverage Metrics
HeartSciences Inc. Total Liabilities Ratios Explained
HeartSciences Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HeartSciences Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HeartSciences Inc. (2020–2026)
The table below shows the annual total liabilities of HeartSciences Inc. from 2020 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-04-30 | $5.04 Billion | +125259.42% |
| 2025-04-30 | $4.02 Million | +83.81% |
| 2024-04-30 | $2.19 Million | -28.49% |
| 2023-04-30 | $3.06 Million | -62.47% |
| 2022-04-30 | $8.15 Million | +112.28% |
| 2021-04-30 | $3.84 Million | +133.92% |
| 2020-04-30 | $1.64 Million | -- |
About HeartSciences Inc.
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related… Read more